PMC8749311_01
Patient and procedure selection.
bmjsit-2019-000024f01.jpg
PMC8749311_01_bmjsit-2019-000024f01.jpg
F1
Patient and procedure selection are shown in figure 1.
Unadjusted survival by drug attribute.
bmjsit-2019-000024f02.jpg
PMC8749311_01_bmjsit-2019-000024f02.jpg
F2
A survival analysis of coronary stents by drug attribute (figure 2) demonstrated no significant differences in unadjusted mortality at 1 year among the various DES: everolimus (27 deaths, 2.5%); zotarolimus (four deaths, 2.6%); and paclitaxel (0 deaths, 0%).
Survival by DES vs BMS. BMS, bare-metal stent; DES, drug eluting stent.
bmjsit-2019-000024f03.jpg
PMC8749311_01_bmjsit-2019-000024f03.jpg
F3
Figure 3 compares the survival of the combined DES cohort with BMS and demonstrates significantly higher unadjusted 1-year mortality in patients receiving BMS (32 deaths, 10.4%) compared with DES (31 deaths, 2.5%) with separation of the curves occurring in the first 40 days and leveling off thereafter.  Figure 3 also contains a survival plot comparing the combined DES with BMS adjusted using propensity score weighting.